For health care professionals only

The information contained on this site is intended for use only by health care professionals in the United States. Countries outside of the United States may have different regulatory requirements or medical practices than the United States. Therefore, this information may not be appropriate for use outside of the United States.

Are you a health care professional in the United States?

You will now be leaving the NovoSeven® RT website.

You don't have to feel alone living with inhibitors.
References
  • Lusher JM, Roberts HR, Davignon G, et al; for rFVlla Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor Vlla in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798.

  • NovoSeven® RT [package insert]. Princeton, NJ: Novo Nordisk Inc; 2010.

  • Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25˚C stable formulation. Haemophilia. 2007;13:527-532.

  • Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958-965.

  • Data on file, Novo Nordisk Inc., Princeton, NJ.

  • Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77(3):131-136.

  • Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia. 2008;14(5):898-902.

  • Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778.

  • Brackmann H-H, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol. 1998;61(suppl 63):18-23.

  • Johannessen M, Andreasen RB, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven®. Blood Coagul Fibrinolysis. 2000;11(3):239-242.

  • Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor [published online ahead of print September 26, 2008]. Blood. doi:10.1182/blood:2008.06-160432.

  • Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13(5):451-461.

  • Collins PW, Hirsch S, Baglin TP, et al; for UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-1877.

  • Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;45(3):200-203.

  • Giangrande P. Acquired Hemophilia: Treatment of Hemophilia No. 38 [monograph]. Montreal, Quebec: World Federation of Hemophilia; 2005.

  • Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol. 2000;22(5):275-278.

  • Centers for Disease Control and Prevention. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families With a New Diagnosis of Hemophilia. Washington, DC: Department of Health and Human Services; 2007.

  • Perry DJ. Factor VII deficiency. Br J Haematol. 2002;118(3):689-700.

  • Ingerslev J, Kristensen HL. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia. 1998;4(1):689-696.

  • Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia. 1997;3(3):215-218.

  • McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EGD. Factor VII deficiency and the FVII mutation database. Hum Mutat. 2001;17(1):3-17.

  • Giansily-Blaizot M, Biron-Andreani C, Aguilar-Martinez P, et al. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding. Br J Haematol. 2002;117(1):172-175.

  • Mariani G, Lo Coco L, Bernardi F, Pinotti M. Molecular and clinical aspects of factor VII deficiency. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S83-S88.

  • Roberts HR, Escobar MA. Less common congenital disorders of hemostasis. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. 2nd ed. Philadelphia, PA: Saunders; 2007:461-462.